Latest Cystic fibrosis Stories
BETHESDA, Md., March 19, 2011 /PRNewswire-USNewswire/ -- Sen. Ron Wyden (D-OR) and Reps. Edward Markey (D-MA) and Cliff Stearns (R-FL) were honored for outstanding leadership on behalf of people with cystic fibrosis during the Cystic Fibrosis Foundation's annual March on the Hill event in Washington, D.C., this week. During March on the Hill, members of the cystic fibrosis community meet with elected officials to raise awareness about the disease. "Senator Wyden, Representative Markey and...
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.Congenital hyperinsulinism (CHI) is a condition where the body's pancreas produces too much insulin "“ rather than too little as in diabetes "“ so understanding the disease has led to breakthroughs in diabetes treatment.This latest study, published in the journal Diabetes today (Wednesday), was...
ROCKAWAY, N.J., March 14, 2011 /PRNewswire/ -- America's largest specialty party retailer, Party City, announces its support of the Cystic Fibrosis Foundation with a nationwide, in-store campaign from March 4 - April 2. Party City customers can support the CF Foundation with dollar donations collected at the registers of its more than 600 retail stores. All donations will help fund CF research, medical and education programs. Together, Party City and the CF Foundation aim to help the...
Agile Sciences' pharmaceutical compounds to be assessed for efficacy against bacterial isolates from cystic fibrosis patients. Raleigh, NC (PRWEB) March 11, 2011 Agile Sciences has been awarded a $75,000 grant from the Cystic Fibrosis Foundation which will facilitate testing of the company's lead pharmaceutical compounds toward bacterial isolates from cystic fibrosis patients. The company will collaborate with a leading cystic fibrosis expert and expects to complete the initial...
RICHMOND, Va., March 3, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) for ARIKACE(TM) (liposomal amikacin for inhalation), Insmed's Phase 3-ready compound for cystic fibrosis (CF) Pseudomonas and non-TB mycobacteria (NTM) lung infections. The PIP covers children from birth to 18 years of...
BOWIE, Md., Feb. 25, 2011 /PRNewswire/ -- Harvey Weiner, who recently joined The MIL Corporation (MIL), a midsized government contractor, has lead an impressive career in consulting, systems integration, and program management services to the Federal government. His most important feat, however, is his fight to find a cure for his son and daughter's disease. The Weiner's daughter, Melissa, 13, and son, Mathew, 16, were both under the age of three when the family learned both children were...
Patients on drug had significant weight gain, reduced sweat chloride and were less likely to experience a pulmonary exacerbation BETHESDA, Md., Feb. 23, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical trial. The trial was designed to evaluate patients age 12 and up who carry at...
The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.The team from the University's Institute of Infection and Global Health took...
Researchers at National Jewish Health and the University of Texas Southwestern Medical Center have discovered a new method to fight bacterial infections associated with contact lenses. The method may also have applications for bacterial infections associated with severe burns and cystic fibrosis. The results were published online January 18 in the journal Investigative Ophthalmology and Visual Science."Infections by the bacteria Pseudomonas aeruginosa can cause severe scarring and vision loss...
INDIANAPOLIS, Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI). During the meeting, the committee had questions about the degree of efficacy of liprotamase and recommended that...
